Last reviewed · How we verify
Hidroferol®
Hidroferol is a vitamin D analog that activates vitamin D receptors to regulate calcium and phosphate metabolism and modulate immune function.
Hidroferol is a vitamin D analog that activates vitamin D receptors to regulate calcium and phosphate metabolism and modulate immune function. Used for Vitamin D deficiency, Hypocalcemia in chronic kidney disease, Hypoparathyroidism.
At a glance
| Generic name | Hidroferol® |
|---|---|
| Also known as | B |
| Sponsor | Hospital Universitario de Canarias |
| Drug class | Vitamin D analog |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Metabolic disorders |
| Phase | FDA-approved |
Mechanism of action
Hidroferol (calcifediol) is a synthetic vitamin D metabolite that binds to vitamin D receptors in target tissues, promoting calcium absorption in the intestine and regulating bone mineralization. It is used to correct vitamin D deficiency and manage disorders of calcium and phosphate metabolism, particularly in patients with chronic kidney disease or hypoparathyroidism.
Approved indications
- Vitamin D deficiency
- Hypocalcemia in chronic kidney disease
- Hypoparathyroidism
- Osteomalacia
Common side effects
- Hypercalcemia
- Hyperphosphatemia
- Nausea
- Headache
Key clinical trials
- Vitamin D Status in Young Medical Residents
- Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism (PHASE3)
- RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients
- REstoration of VItamin D in Pulmonary Arterial Hypertension (PHASE4)
- CCEF in the Treatment of Acute VFFs: Randomized Controlled Trial (NA)
- Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD) (PHASE4)
- Zurich Disability Prevention Trial (PHASE2)
- Effect of Omega-3 Fatty Acid on Vitamin D Activation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hidroferol® CI brief — competitive landscape report
- Hidroferol® updates RSS · CI watch RSS
- Hospital Universitario de Canarias portfolio CI